Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma

Ding ShengNan; Yang WeiMin; Niu JunQi

doi:10.3969/j.issn.1001-5256.2014.06.020

Issue 6

Jun. 2014

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2014 > 30(6): 556-559

PDF( 1204 KB)

Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2014.06.020

Department of Hepatobiliary and Pancreatic Diseases, The First Hospital of Jilin University

Received Date: 2014-04-23
Published Date: 2014-06-20

Abstract

Abstract

Objective To analyze the changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma ( HCC) . Methods The clinical data of 602 cirrhotic patients with HCC who were admitted to the First Hospital of Jilin University from January 2011 to December 2012, as well as 200 cirrhotic patients hospitalized during the same period, were collected. Statistical analysis was performed using SPSS 19. 0. Normally distributed continuous data were expressed as mean ± standard deviation; comparison between two groups was made by t test, and comparison between multiple groups was made by analysis of variance. Non- normally distributed data were expressed as median and interquartile range ( P25- P75) ; comparison between groups was made by rank sum test. Results Compared with the cirrhotic group, the HCC group had significantly higher platelet count ( PLT) and plateletcrit ( PCT) ( t = 5. 019, P = 0. 000;t = 5. 017, P = 0. 000) and a significantly lower mean platelet volume ( MPV) /PLT ( t = 5. 877, P = 0. 000) ; there were no significant differences in MPV and platelet distribution width between the two groups ( t =- 0. 942, P = 0. 347; t =- 1. 040, P = 0. 298) . The receiver operating characteristic ( ROC) analysis showed that the area under the ROC curve was 0. 636 for PLT, 0. 633 for PCT, and 0. 639 for MPV /PLT in the diagnosis of HCC in cirrhotic patients. Decreases in PLT and PCT were closely related to hepatitis C virus ( HCV) infection. Patients with Child- Pugh class A cirrhosis had significantly higher PLT and PCT than those with Child- Pugh class B and C cirrhosis ( P <0.01) ; patients with a maximum tumor diameter of ≥5 cm had significantly higher PLT and PCT than those with maximum tumor diameters of 2- 5 cm and ≤2 cm ( P < 0. 01) . Patients with Child- Pugh class A cirrhosis had a significantly lower MPV /PLT than those with Child- Pugh class B and C cirrhosis ( P < 0. 01) ; patients with a maximum tumor diameter of ≥5 cm had a significantly lower MPV /PLT than those with maximum tumor diameters of 2- 5 cm and ≤2 cm ( P < 0. 01) . Conclusion PLT, PCT, and MPV /PLT can be used in the auxiliary diagnosis of HCC in cirrhotic patients, which are related to HCV, Child- Pugh classification, and tumor size.
- liver neoplasms,
- liver cirrhosis,
- blood platelet,
- root cause analysis

FullText(HTML)

References(17)

References

[1]NOZAKI R, MURATA S, NOWATARI T, et al.Effects of thrombopoietin on growth of hepatocellular carcinoma:Is thrombopoietin therapy for liver disease safe or not?[J].Hepatol Res, 2013, 43 (6) :610-620.

[2]LATVALA J, PARKKILA S, NIEMEL O.Excess alcohol consumption is common in patients with cytopenia:studies in blood and bone marrow cells[J].Alcohol Clin Exp Res, 2004, 28 (4) :619-624.

[3]JENNE CN, URRUTIA R, KUBES P.Platelets:bridging hemostasis, inflammation, and immunity[J].Int J Lab Hematol, 2013, 35 (3) :254-261.

[4]CHEN CC, CHANG JY, LIU KJ, et al.Hepatocellular carcinoma associated with acquired von Willebrand disease and extreme thrombocytosis[J].Ann Oncol, 2005, 16 (6) :988-989.

[5]HWANG SJ, LUO JC, LI CP, et al.Thrombocytosis:a paraneoplastic syndrome in patients with hepatocellular carcinoma[J].World J Gastroenterol, 2004, 10 (17) :2472-2477.

[6]CARR BI, GUERRA V.Thrombocytosis and hepatocellular carcinoma[J].Dig Dis Sci, 2013, 58 (6) :1790-1796.

[7]BERGER FG.The interleukin-6 gene:a susceptibility factor that may contribute to racial and ethnic disparities in breast cancer mortality[J].Breast Cancer Res Treat, 2004, 88 (3) :281-285.

[8]PORTA C, DE AMICI M, QUAGLINI S, et al.Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma[J].Ann Oncol, 2008, 19 (2) :353-358.

[9]GIANNITRAPANI L, CERVELLO M, SORESI M, et al.Circulating IL-6 and sIL-6R in patients with hepatocellular carcinoma[J].Ann N Y Acad Sci, 2002, 963:46-52.

[10]MALAQUARNERA M, DI FAZIO I, LAURINO A, et al.Role of interleukin 6 in hepatocellular carcinoma[J].Bull Cancer, 1996, 83 (5) :379-384.

[11]MARRERO JA, FENG Z, WANG Y, et al.Alpha-fetoprotein, desgamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma[J].Gastroenterology, 2009, 137 (1) :110-118.

[12]WANG CS, YAO WJ, WANG ST, et al.Strong association of hepatitis C virus (HCV) infection and thrombocytopenia:implications from a survey of a community with hyperendemic HCV infection[J].Clin Infect Dis, 2004, 39 (6) :790-796.

[13]GIANNINI EG, SAVARINO V.Further insights into the causes of thrombocytopenia in chronic hepatitis C[J].J Gastrointestin Liver Dis, 2010, 19 (4) :357-358.

[14]LI Q, SUN GZ, WANG BE, et al.The relationship among the counts of platelet, thrombopoietin and spleen index in patients with liver cirrhosis[J].Chin J Hepatol, 2004, 12 (4) :210-212. (in Chinese) 李琴, 孙桂珍, 王宝恩, 等.肝硬化患者血小板计数与血小板生成素及脾脏指数间的关系[J].中华肝脏病杂志, 2004, 12 (4) :210-212.

[15]CARR BI, GUERRA V, PANCOSKA P.Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma[J].Oncology, 2012, 83 (6) :339-345.

[16]CARR BI, GUERRA V, DE GIORGIO M, et al.Small hepatocellular carcinomas and thrombocytopenia[J].Oncology, 2012, 83 (6) :331-338.

[17]CARR BI, GUERRA V.Hepatocellular carcinoma size:platelets, γ-Glutamyl transpeptidase, and alkaline phosphatase[J].Oncology, 2013, 85 (3) :153-159.

Relative Articles

[1]	Wang ZhiXin, Li Yao, Zhou LiuXin, Ren Li, Qu Kai, Miao Run, Hou LiChao, Wang HaiJiu, Liu Chang, Fan HaiNing. Influence of 5-hydroxytryptamine and platelet count in peripheral blood on the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1534-1539. doi: 10.3969/j.issn.1001-5256.2020.07.017
[2]	Lu Qian, Zhu Li, Cheng Xin, Huang Hua, Chen Zhong. Expression of proteasome subunit beta type 4 in hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 372-376. doi: 10.3969/j.issn.1001-5256.2020.02.028
[3]	Zhang DaLi, Feng DanNi, Zhang LiJuan, Tang RuJia, He Xi, Zhou Xia, Gao YinJie, Liu ZhenWen, Liu HongLing. Risk factors for recurrence after liver transplantation in patients with hepatocellular carcinoma and their prognosis[J]. Journal of Clinical Hepatology, 2020, 36(9): 1985-1989. doi: 10.3969/j.issn.1001-5256.2020.09.015
[4]	Ye YingJian, Liu Bo, Chen Wei, Li QiongXia. Prognosis and staging system analysis of hepatocellular carcinoma patients with negative serum alpha-fetoprotein[J]. Journal of Clinical Hepatology, 2019, 35(3): 535-541. doi: 10.3969/j.issn.1001-5256.2019.03.017
[5]	Zang YouYa, Long PeiYun, Han ZhiWei, Wang Huan, Ruan JingSheng, Huang Shan, Wu GuoBin, Chen Chuang. Establishment and verification of a nomogram for predicting patient prognosis after hepatectomy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(10): 2225-2230. doi: 10.3969/j.issn.1001-5256.2019.10.019
[6]	Chen Chuang, Long PeiYun, Chen Jie, Wang Pan, Huang QingYun, Zang YouYa, Deng GuoYu, Lin DongYi, Wang ZongYu. Value of Barcelona Clinic Liver Cancer staging system versus Hong Kong Liver Cancer staging system in predicting the prognosis of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(3): 530-534. doi: 10.3969/j.issn.1001-5256.2019.03.016
[7]	Tang Ling, Qiu LuDie, Qin Wen, Wu Gang. Expression of circular RNA FLI1 in patients with hepatocellular carcinoma and its association with prognosis[J]. Journal of Clinical Hepatology, 2019, 35(9): 1980-1984. doi: 10.3969/j.issn.1001-5256.2019.09.019
[8]	Luo Hao, Huang Jun. Clinical value of albumin-bilirubin grade in evaluating the prognosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1608-1612. doi: 10.3969/j.issn.1001-5256.2019.07.040
[9]	He YaJing, Zhang ZhiMing, He WeiMeng, Hou JinLin. Epidemiological characteristics and prognosis of hepatocellular carcinoma: A single-center observational real-world cohort study of 1302 cases[J]. Journal of Clinical Hepatology, 2019, 35(5): 1002-1007. doi: 10.3969/j.issn.1001-5256.2019.05.014
[10]	Zhu Feng, Feng XiaoHai, An Yue. Association between the expression of somatostatin receptors and pathological features, prognosis in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(2): 314-320. doi: 10.3969/j.issn.1001-5256.2018.02.019
[11]	Yang GuiMin, Zhao YunSheng, Wang ChunHua, Jin Liang. Research advances in tumor markers for the diagnosis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2018, 34(1): 199-203. doi: 10.3969/j.issn.1001-5256.2018.01.044
[12]	Xia DongDong, Wang EnXin, Wang WenJun, Bai Wei, Yuan Jie, Han GuoHong. Early alpha-fetoprotein response can predict the prognosis of patients with intermediate-stage hepatocellular carcinoma treated with transarterial chemoembolization[J]. Journal of Clinical Hepatology, 2017, 33(6): 1120-1125. doi: 10.3969/j.issn.1001-5256.2017.06.021
[13]	Ma ShiJie, Zou ShaoJing, Luo XiaoLing, Li QianJun, Huang JiaSheng. Prognostic factors for transcatheter arterial chemoembolization in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(1): 80-83. doi: 10.3969/j.issn.1001-5256.2016.01.013
[14]	Wang XianBo, Gao FangYuan, Liu Yao. Neutrophil- lymphocyte ratio: a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 649-652. doi: 10.3969/j.issn.1001-5256.2016.04.007
[15]	Yang XiaoXiao, Ma Hong. Research advances in tumor markers of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2016, 32(4): 811-815. doi: 10.3969/j.issn.1001-5256.2016.04.047
[16]	Li Peng, Zhai Yun, Zhang ShiBin, Li Lei, Ding HuiGuo. Analysis of quality of life and prognosis in patients with HBV-related end-stage hepatocellular carcinoma after antiviral therapy[J]. Journal of Clinical Hepatology, 2015, 31(5): 721-724. doi: 10.3969/j.issn.1001-5256.2015.05.021
[17]	Wang JianGang, Li HuaCheng, Fei XinYing. Application of metabolomics in research on biomarkers for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(8): 836-838. doi: 10.3969/j.issn.1001-5256.2014.08.039
[18]	Jia Jia, Qi XingShun, Han GuoHong. Prognostic value of α-fetoprotein response in treatment of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2013, 29(8): 576-580. doi: 10.3969/j.issn.1001-5256.2013.08.006
[19]	Zhang LiJun, Jia XiaoFang, Teng ZhenLin, Cheng NengNeng. Biomarkers of liver cancer related to hepatitis B virus selected by proteomics[J]. Journal of Clinical Hepatology, 2011, 27(5): 553-557.
[20]	Ren YiBin, Wang HongYang. The progress of diagnostic marker in hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2010, 26(4): 358-360+364.

Supplements(0)

Cited By

Cited by

Periodical cited type(11)

1.	顾智文. 射频消融术联合奥沙利铂加卡培他滨方案用于结直肠癌术后肝转移患者的临床价值. 大医生. 2024(01): 25-28 .
2.	刘炫鳞，买佳琪，马文兵. 脾多肽注射液联合西妥昔、mFOLFOX6方案对直肠癌肝转移患者生存质量及TRF1、TRF2表达的影响. 临床医学研究与实践. 2023(25): 29-32 .
3.	林守英，周庄，刘丽雅. 薏苡附子败酱散联合XELOX方案对结直肠癌患者免疫功能、肠道菌群的影响. 实用中西医结合临床. 2023(21): 37-40 .
4.	张洋，杨帆，王景景. 沙利度胺联合XELOX方案化疗治疗转移性结直肠癌的疗效及对生存率的影响. 癌症进展. 2022(07): 727-730 .
5.	苏华冠，谢礼福，刘奕武，赖光芒. 腹腔镜下结直肠癌切除术联合肝转移瘤射频消融术治疗结直肠癌肝转移. 中国肝脏病杂志(电子版). 2021(02): 13-18 .
6.	王强. 经皮肝射频消融术联合经导管肝动脉灌注化疗治疗晚期结直肠癌多发肝转移瘤患者的效果. 中国民康医学. 2021(23): 19-22 .
7.	刘信，刘放，刘也夫，谢峰，张睿. 术中开腹彩超引导下射频与经皮CT引导射频治疗结直肠癌肝转移疗效比较研究. 临床军医杂志. 2020(02): 167-169 .
8.	高岩，蓝宇，贾纯增. 内镜黏膜下剥离术治疗早期结直肠癌及癌前病变临床效果观察. 临床军医杂志. 2020(06): 668-671+675 .
9.	吕厚宽，庄文辉，刘晓晖，郭泽才，刘琪. 卡培他滨联合奥沙利铂治疗直肠癌的临床疗效研究. 长春中医药大学学报. 2020(04): 741-744 .
10.	李江，候宇，蔡晓蓓，徐承雷，易根发. 基于限制性肝段切除手术的局部治疗模式改善结直肠癌术后肝脏寡转移的预后分析. 临床肝胆病杂志. 2020(08): 1763-1767 . 本站查看
11.	彭文杰. AFP、CCL2和HP在结直肠癌肝转移诊断中的临床应用研究. 国际生物医学工程杂志. 2019(05): 414-418 .

Other cited types(1)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (3285) PDF downloads(658)

Changes in platelet parameters and their influential factors in cirrhotic patients with hepatocellular carcinoma

DOI: 10.3969/j.issn.1001-5256.2014.06.020